You are here

Pinned

Please help with a short questionnaire

Categories:

An investigation of patient experience with and perception of generic TKIs for the treatment of CML.

A pharmacy student at Birmingham University (which is where I studied, so I have a particular affinity for research there!) has designed an online survey to find out about CML patients’ experiences with and opinions of generic TKIs. The survey has full ethical approval and is designed to be quick and easy to complete. Any patient currently taking a TKI is eligible to take part, with no restrictions on what part of the world you are in .

If you want to have your voice heard on this really important topic and have just a few minutes to spare, please click on the link below. It’s a pretty short survey, so won’t take you long.

https://app.onlinesurveys.jisc.ac.uk/s/bham/an-investigation-of-patient-...

Thanks,
David.

Done mate.

Al

Done

Done.

Done.

Done

Duly completed

Done

Done

Done.

I had no problem moving from dasatinib Sprycel to Zentiva and Teva generics.

Previously, I suffered greatly in using the various imatinib generics.

The pharmacist will tell us that the different fillers cause varying side effects.

However, suppose I list all of the additives to the active ingredient contained in Lansoprazole/Linagliptin/Losartan/Metformin/Pravastatin/Tadalafil/Tamsulosin/Amitriptyline. Why do those additives, which are similar or the same as those in the different imatinib generics, not have an ill effect?

Why is it that dasatinib generics were good for me, whereas imatinib generics most certainly were not?

Do pharmacists accept that the CML community observations are real rather than imagined?

Hi,
Many thanks for completing the questionnaire - your experience is really interesting. I am supervising this project and as a pharmacist working with CML patients I have seen first hand the issue with differing side effects depending on which specific generic is being taken. So I totally agree that the CML community observations are real! We are hoping to do a prospective follow up study where patients will have the opportunity to record daily toxicities alongside details of which specific generic they are taken. In the meantime, the survey will be closing in the next couple of days so any final responses would be greatly appreciated.
Thanks again to everyone who has completed the survey.
Nick Duncan

Done

Done !